

Index

A

- AAN, 109, 118, 189, 197
 abdominal pain, 168–9
 abnormal EEG, 98, 102–4, 179, 181
 abnormalities, 17, 18, 19, 27, 30, 35, 38, 45, 47, 51, 57, 61, 62, 92, 102, 152, 169
 neurological, 103, 105
 pathological, 91, 163
 absence seizures, 13, 59, 68, 70–1, 80, 82, 89–90, 105, 110, 114, 116, 119, 122, 158, 179
 abuse, 14, 26, 56
 accommodations, 235
 acetazolamide, 112, 120, 122, 168, 193
 acidosis, 119, 168, 221, 225
 metabolic, 167–8
 ACTH, 117, 121
 activating procedures, 18
 acupuncture, 154
 acute symptomatic seizure, 6, 7, 56, 57, 61, 65
 ADA (Americans with Disabilities Act), 235–6
 add-on treatment, 70, 145
 adherence, 94, 132, 167, 178, 197, 227, 234
 adjunctive treatment, 134, 137
 adolescents, 1, 2, 11, 16, 54, 65, 78, 93–4, 98, 109, 115–16, 149, 152–3, 161, 183, 231, 233
 adults, 113–16, 122, 137, 147, 150, 164–5, 167, 169, 177–8, 181, 183–4, 186, 211–12, 222, 224–5
 young, 95, 231
 younger, 151, 219
 adverse effect profiles, 111, 135–6
 adverse events, 99, 129, 132–3, 136, 140–1, 143, 149, 151–2, 172–3, 202, 218
 AEDs
 adverse effects, 101, 113–14, 132–4, 137, 144–6, 165, 168, 174, 177, 184–5, 187, 190, 195, 199–200, 202
 carbonic anhydrase-inhibiting, 168
 appropriate, 106, 159–60, 224
 average doses, 141
 baseline, 173
 classic, 109, 115, 128–9, 132–3, 141
 combinations, 144, 174
 comedication of, 130–1
 common doses, 140, 147
 compliance, 220, 226
 concentration, 148
 current, 99, 106, 134, 160, 198, 225
 daily dose, 141–4, 195
 discontinuation of, 90, 117, 133, 151–2, 160, 164, 168, 175, 178–81, 183–7, 206
 dose increments, 140–2, 144, 171–3
 effectiveness, 113–15, 117, 140–1, 185
 emergencies, 215
 enzyme-inducing, 129, 145, 151, 153, 171, 190, 211
 enzyme-inhibiting, 149
 first, 109, 140–1, 143–5, 172–3, 225
 first-ever, 99, 140–1
 first-generation, 132
 idiosyncratic reactions, 108, 127–8, 145–6, 157, 224
 individual, 115
 interaction profile of, 128
 maintenance doses, 134, 141, 152
 marketed, 97, 112, 119
 modern, 109
 molecular action of, 124
 monotherapy, 146, 149, 151
 new-generation, 113
 new, 108–9, 112–13, 115–17, 120, 122, 129, 132–4, 137
 newer, 113, 115, 128–9, 132–4, 137, 141–2, 146, 148, 151–2
 nonenzyme-inducing, 153
 noninducing, 132
 noninteracting, 129
 old, 104, 113, 115, 132–4, 173, 211
 optimal, 111
 past, 145
 plasma concentrations, 148–9
 preferred, 109
 restarting, 183, 186
 risk-benefit profile, 110
 second-generation, 111–12, 136
 second-line, 117, 224
 second, 143, 145, 173
 side effects, 171
 single, 172
 starting, 97–8, 100, 104–5
 stopping, 97, 172, 175–9, 183–6
 substitution, 109, 145–6, 173
 switching, 175
 tapering, 178, 184, 224
 target doses, 141
 teratogenic effects of, 116, 133
 third-generation, 112–13, 132–3, 136
 weight neutral, 128
 withdrawal of, 77, 119, 140, 164, 176–86, 196–7, 206, 212, 215, 223–4
 age, 13, 16, 47, 61, 81–4, 87–90, 92, 94–5, 114, 116–17, 150–1, 153, 159, 165, 178–82, 189, 200–1, 208, 218–19
 aging, 148, 150, 165
 agitation, 92, 205
 albumin, 147, 151, 199
 alcohol, 5, 18, 51, 56, 89, 94, 99, 130, 197, 202, 215, 220, 226, 229

Index

- allergies, 14
alprazolam, 26, 56
alternative therapies, 123, 158
Alzheimer's disease, 150
American Academy of
 Neurology, 109, 197
Americans with Disabilities
 Act (ADA), 235–6
amitriptyline, 212
ammonia, 132
Ammon's horn sclerosis, 44
amnesia, 9, 12, 15, 26, 72, 74,
 78, 81–3, 134, 151
 gap, 79
 global, 74, 78, 82–3
amoxapine, 210, 212
amphetamine, 55–6
amygdalohippocampectomy, 32
androgens, 153, 191
anesthesia, general, 223–5
Angelman's syndrome, 93
angioma, 88
anhedonia, 207
anhidrosis, 110, 119
animal models, 124–5, 127,
 137
anoxic seizures, 5, 7
antiarrhythmic agents, 21
antibiotics, 73, 129, 149
antibodies, 95
antibody titers, 95
anticholinergics, 80
anticoagulants, 130–1
anticonvulsant effect, 125–6,
 154, 210
anticonvulsants, 190, 215
antidepressants, 206, 209–11
 particular, 211
 tricyclic, 210
 underutilizing, 210
antiemetics, 80, 168
antiepileptic drugs, 97, 108,
 118, 145, 161, 181–2, 206,
 232
antihyperglycemics, 80
antiplatelet agents, 21
antipsychotics, 9, 18, 63, 80
antiseizure drug (ASD), 1, 49
anxiety, 5, 6, 11, 12, 14, 16,
 26, 37
 comorbid, 208
 disorders, 128–9, 205–7,
 209, 211, 213
 excessive, 206
 interictal, 206
 parental, 233
 postictal, 206
 preictal, 206
 social, 233
anxiolytics, 16
aphasia, 58
aphasia, 82, 91, 94
apneas, 11, 81
apoptosis, 198
appendicitis, 169
appetite, 205, 208
aromatherapy, 154
arousals, 81, 92, 194
assessment, 66, 70, 91, 97, 100,
 103, 108, 162–3, 175, 194,
 202, 226–7
 diagnostic, 66
 endocrine, 194
 neuropsychological, 163
 prognostic, 103
ataxia, 72, 151
atrial fibrillation, 7, 9, 56, 57
attacks, 68, 71, 75–9, 84,
 89–90, 161, 206
 ischemic, 82, 84
 rage, 77, 81
attention deficit disorder,
 11–12, 30
attention deficit hyperactivity
 disorder, 14, 55
auras, 9, 12, 15, 54, 58, 82–3,
 85, 91–2, 164, 184
 isolated, 91
 visual, 83, 92
authorities, regulatory, 230–1
autism, 30, 77–8
autistic spectrum disorder,
 18, 63
autoimmune epilepsy, 95
automatisms, 69, 79–80, 83–4,
 91, 192
autosomal-dominant
 nocturnal frontal lobe
 epilepsy, 87
awareness, 7, 13, 15, 26, 39, 54,
 58, 63, 67–9, 75, 80, 83,
 100, 151
 altered, 227
 impaired, 67, 78, 201
- B**
babies, 197, 199–200
back arching, 15, 26, 27
baclofen, 18, 63
barbiturates, 56, 111, 198, 213,
 221, 223
 sedative, 111
 bathing, 199, 233
 Beck Anxiety Inventory, 207
 Beck Depression Inventory-II,
 208
 benefit-to-risk ratio, 115, 172
 benzodiazepines, 56, 111–12,
 124–5, 130, 193, 206, 212,
 217, 219–20, 222–5
 first-line, 224
 bentropine, 80
 bicarbonate, 166, 168, 225
 biofeedback, 154
 birth control pills, 195
 birth defects, 198
 biting, 13, 14, 15, 16, 28
 bladder, 53
 blank stare, 15, 58
 bleeding, 66, 166, 195,
 199–200, 227
 blindness, 18, 30, 63
 blood glucose, 220, 226
 blood pressure, 26, 66, 212,
 218, 221–2, 225, 227
 systolic, 7
 blood-brain barrier, 157
 blurry vision, 60
 body mass index, 127–8
 brain
 fog, 11
 insult, 56
 surgery, 56
 tumor, 9, 43
 brain insults, 91, 127, 134
 severe, 73
 brain lesion, 220, 226
 breakthrough seizures, 199
 breastfeeding, 189, 197, 200
 breath-holding, 11, 12
 brivaracetam, 112, 120, 122,
 142
 bromide, 112, 120–1, 142
 bruising, 166
 bullying, 14
 bupropion, 210
 burns, 233–4
- C**
calcium, 202
cancer, 128–9, 149, 200
carbamazepine, 1, 27, 32, 37,
 39, 70, 80, 108–10, 119,
 123, 125, 130, 136, 140–2,
 147, 157, 174, 177, 191–2,
 196, 206
 carbamazepine, older agents,
 129

- carbohydrates, 166–9
 carbonic anhydrase, 167–8
 cardiac arrhythmia, 4, 5, 7, 25
 caregivers, 11, 73, 85, 98, 100, 199
 carnitine, 167, 169
 catamenial seizures, 193, 201
 cauda equina-conus medullaris syndrome, 217
 cavernous vascular malformation, 49, 61
 CBT (cognitive behavior therapy), 154, 211–13
 CBZ, 108–16, 123–4, 127–30, 132–4, 136, 140–2, 144–6, 149, 151–3, 157–61, 177, 192, 194–5, 198, 210
 CDI (Children's Depression Inventory), 208
 cerebral ischemia, 9, 56
 cerebral palsy, 18, 30, 63
 cerebrovascular disease, 5, 43, 56
 childbearing, 127–8, 133, 144, 174
 childhood, 68, 83–4, 87–8, 90, 93, 187, 222
 absence epilepsy, 86–7, 93, 187
 behavior problems, 93
 early, 200
 epilepsy, 166, 181
 new-onset absence epilepsy of, 116–17
 onset epilepsy, 90, 93, 150, 183
 children, 3, 11, 14, 30, 40, 45, 46, 53, 54, 55, 62, 65
 Children's Depression Inventory (CDI), 208
 Chinese medicine, 154
 chlordiazepoxide, 112
 choking, 206
 cholesterol, 128, 169
 elevated, 169
 high, 169
 total, 169
 chronic epilepsy, 127, 150, 172, 207, 215
 uncontrolled, 142, 172
 chronic pain, 2, 13–14, 26, 27
 citalopram, 26, 210–12
 classification, 3, 4, 19, 40, 58, 66–9, 85–8, 90–1, 93, 103, 114
 clinical, 66
 CLB, 128, 136
 clinical trials, 133, 151, 207, 210, 218
 comparative, 151
 prospective, 218
 clobazam, 112, 119–20, 122–4, 136, 142, 145, 193, 196
 clomipramine, 210–12
 clonazepam, 1, 37, 56, 145, 220, 226
 clonic seizures, 67–70, 72–3, 75, 79–80, 86–9, 93, 102, 106, 123, 160, 179–81, 216–17, 220, 229, 232
 cocaine, 99
 Cochrane Library, 114
 cognitive
 changes, 71, 150
 deficits, 102, 109, 183
 functions, 150
 impairment, 83, 150, 157, 161, 208, 229
 side effects, 110, 119, 177
 cognitive behavioral therapy, 3, 16, 20, 21. *See also* CBT
 cognitive dysfunction, 11, 59
 coma, 9, 71, 73, 218, 224
 combination therapy, 117, 129, 144–5, 212
 two-drug, 174
 unnecessary use of, 144, 174
 comedication, 127–8, 210
 co-morbidities, 87, 99, 108, 117, 120, 127, 149–51, 178, 215, 235
 complacency, 99, 161
 complementary medicine, 153–4, 156
 compliance, 148–9, 151–2, 172, 195, 197, 231
 complications, 99, 129, 136, 164–7, 169, 186, 199, 215, 217, 221, 225, 227, 229, 232–3
 concentration, 98, 129, 147–9, 152, 161, 172, 185, 199–200, 205–6, 210–11, 224, 233
 confusion, 1, 6, 9, 11, 12, 38, 59, 67, 72, 75, 78, 83, 91, 94, 206, 215, 226, 230
 episodic, 83
 congenital malformations, 195, 198
 consciousness
 impairment of, 67, 83, 215
 loss of, 5, 6, 9, 11, 12, 19, 28, 39, 51, 53, 54, 55, 58, 59, 67–8, 72, 79–80, 82–4, 197
 consent, informed, 97, 100, 186
 constipation, 169
 contraceptives, 129, 193, 195–6, 199
 conversion disorder, 12, 15, 16
 convulsions, 3, 6, 7, 9, 54, 55, 58, 59, 60, 73, 79, 83, 124, 151, 159, 218, 220–1, 223–5
 convulsive seizures, 25, 55, 59
 cortical dysplasia, 44, 46, 47, 61
 corticosteroids, 95, 112, 131
 costs, 97, 99, 108, 117, 120, 127, 143, 157, 173, 231, 233–5
 craniotomy, 13, 32
 crying, 11, 205
 cryptogenic, 92–3, 105
 cursing, 16
 cyanosis, 7, 28
 cyclophosphamide, 95
 cyclosporine A, 130–1
 CYP450, 128, 151, 195, 210
 cysts, 190–1
- D**
 daydreaming, 12
 death, 7, 21, 27, 50, 73, 90, 157, 161, 205–6, 215–16, 231
 accidental, 233
 epilepsy-related, 90
 maternal, 199
 neonatal, 198
 seizure-related, 164
 sudden unexpected, 197
 unexplained, 90
 dehydration, 226
 déjà vu, 7, 28, 54, 58
 delayed treatment, 101, 103–4, 217
 delirium, 5
 dementia, 30
 dementias, 150
 de-novo absence status, 94

Index

- depression, 1, 2, 5, 14, 26, 37, 72, 109, 119, 127–9, 133, 135, 204–13, 222, 225
 in children and adolescents, 94
 diagnose, 209
 evaluating, 207
 ictal, 205
 interictal, 205
 minor, 205
 patient's, 209
 possible, 207
 postictal, 205, 208
 significant, 204
 symptoms of, 205, 213
 desipramine, 212
 developmental delay, 181–2
 dextroamphetamine, 55
 dextrose, 168, 221
 diabetes, 6, 7, 9, 128, 191, 200
 diagnosis of epilepsy, 66, 74, 83, 98, 100, 144, 174, 186, 209, 230
 diagnostic errors, 66, 151
 diaphoresis, 168, 212
 diarrhea, 169
 diazepam, 112, 218–25
 diazepam/carbamazepine, 112
 diazepam/fosphenytoin, 219
 diazepam/phenytoin, 219, 223
 diet, 119, 124, 154, 156, 166–9, 197
 healthy, 197
 high-fat, 166
 ketogenic, 119, 124, 156, 166–8
 low-fiber, 169
 differential diagnosis, 69, 71, 76, 83–4, 151, 226
 digitalis-glycosides, 130–1
 diltiazem, 130–1
 diphenhydramine, 80
 disability, 103, 204–5, 209, 235
 learning, 103
 disabling seizures, 106, 164
 severe, 162
 discrimination, 233, 235–6
 disease
 bone, 152, 201–2
 cardiovascular, 128
 cerebrovascular, 150, 219
 coronary artery, 100
 disorders, 83, 91, 94–5, 113, 128–9, 149, 151, 158, 171, 204, 209, 213, 233
 bipolar, 208, 211, 213
 dysthymic, 205, 211
 neurodegenerative, 84, 93
 neuronal migration, 93
 obsessive-compulsive, 206
 paroxysmal movement, 74
 posttraumatic stress, 206
 psychological, 81
 disorientation, 1, 4, 6, 15
 divalproex, 196
 dizziness, 11, 60
 documentation, 70, 171, 174
 donepezil, 130–1
 dopamine, 9
 dopamine receptor blockers, 80
 dose adjustments, 144, 148, 174
 dose–response relationships, 144, 174
 doses, lowest, 140–1
 doxepin, 212
 doxycycline, 130–1
 Dravet and Doose syndromes, 167
 Dravet syndrome, 87, 120, 122, 124
 dreams, 81, 84
 driving, 4, 54, 57, 63, 74, 94, 102, 171, 185, 201, 213, 230–1
 drop attacks, 81, 90, 161
 drowsiness, 29, 34, 37, 38, 50, 63
 drug combinations, 144, 174
 drug compliance, 149, 152
 irregular, 147
 self-monitor, 99
 drug concentrations, 148
 measuring free, 199
 monitoring serum, 144, 174
 serum, 144, 174
 drug discontinuation, 133, 180–1, 183
 drug elimination, 198, 200
 drug interactions, 110–13, 119, 128–9, 132–3, 136, 144–6, 148–9, 151–3, 172, 174, 177, 185, 187, 195, 212
 absence of, 128
 adverse, 113, 132, 145–6
 low risk of, 110
 drug load, 143, 145, 173
 drug metabolism, 122, 128
 drug monitoring, 146–9
 drug resistance, 156–8, 161, 172, 185
 drug response, 87, 156, 158–60
 drug toxicity, 144, 147
 clinical, 185
 organ, 144
 drug treatment, 92, 98–100, 102, 137, 146, 156, 163, 179, 185–7, 215, 219, 224
 single, 70, 133
 withholding, 144, 174
 drug use, 94
 drug–drug interactions, 60, 128, 144, 148–9, 152, 174, 212
 drug-resistant epilepsy, 75, 89, 103, 120, 122, 137, 145, 148, 153, 156–66, 172, 183, 201, 204–6, 210–11
 chronic, 183
 drug-resistant seizures, 13
 drugs, 5, 16, 21, 25, 51, 53
 DSM-III, 150
 duloxetine, 211
 dysarthria, 58
 dyslipidemia, 169, 191
 dyspareunia, 194
 dysphoria, 72
 dysplasia, 102, 163
 dysrhythmia, 89
- E**
 education, 149, 167, 233–4
 EFA Concerns Index, 232
 efficacy, 97, 99, 108–10, 113–17, 119–20, 122, 124, 127, 131, 137, 140, 149, 153, 157, 195–6
 elderly, 12, 59, 83–4, 90, 94, 109, 114, 119, 128, 134, 148–52, 165, 202, 212, 218–21, 223, 226
 electroconvulsive therapy, 211–12
 electrographic seizure, 18, 36
 emergencies, 89, 142, 199, 215–27
 emesis, 132, 168–9
 emotional triggers, 75
 emotionality, 205
 employment, 94, 229, 232–3, 235–6
 encephalomalacia, 17
 encephalopathy, 30, 73, 85, 87, 135
 endocrine function, 153, 190
 male, 153
 endogenous substances, 128–9

- enzyme inhibition, 108, 129
 enzyme-inducing agents,
 127–8, 134, 144, 174
 enzyme-inducing drugs, 128
 eosinophilia, 26
 epidermal necrolysis, 123
 epilepsy partialis continua,
 215
 epilepsies of unknown cause,
 88, 92–3
 epilepsy
 autoimmune, 92, 95
 benign, 87, 93, 114, 181
 catamenial, 190, 193–4
 catastrophic, 93
 classification, 85–6
 cryptogenic, 90–1
 drug-refractory, 103
 drug-responsive, 164
 duration, 181–2, 184
 extratemporal, 164
 foundation, 230
 idiopathic, 92–3
 multi-focal, 162
 myoclonic-astatic, 93
 non-lesional, 162
 post-stroke, 101
 primary reading, 98, 161
 recent-onset, 115
 unclassified, 116
 uncontrollable, 186
 untreated, 104, 114, 140
 Epilepsy Foundation's Mood
 Disorders Initiative, 212
 epilepsy monitoring units
 (EMUs), 5
 epilepsy surgery, 36, 43, 46,
 91–2, 95, 153, 162–5, 167,
 172, 175, 235
 resective, 163, 165
 epilepsy syndromes, self-
 limiting, 181–2
 epileptic encephalopathies, 72,
 85, 87, 93
 epileptiform abnormality, 14,
 32, 51, 62, 101, 181–2
 epileptiform activity, 66, 76,
 81, 194, 222–4
 epileptiform changes, 73, 212
 epileptiform discharges (EDs),
 3, 25, 29, 30, 49, 63
 epileptogenesis, 93, 134, 217
 epileptologists, 85
 episodes
 psychotic, 110
 syncope, 77, 79–80
 erectile dysfunction, 153, 194
 errors
 common, 66, 149, 171–2
 in diagnosis, 69
 escalation rates, 144, 173
 escitalopram, 210–12
 ESL, 136
 eslicarbazepine, 70, 109–10,
 118–19, 123, 130, 136,
 141–2, 147, 196
 ESM, 111, 116–17, 122, 136
 estrogen, 190, 192–3
 ethnicity, 95, 123
 ethosuximide, 70, 109–12,
 116, 121, 123, 136, 141–2,
 147, 196
 evaluation, 80, 82, 89, 169, 172,
 205, 207, 226, 235
 presurgical, 95, 162–3, 172
 surgical, 94
 evaluation process, 64
 everolimus, 112
 exacerbation, catamenial,
 193–4
 examination, 66, 75, 88–90,
 100–2, 106, 164, 184,
 190–1, 204, 216, 220,
 226
 exercise, 99, 202, 213
 expidet, 226
 extratemporal focal seizures,
 13
 eyes, 1, 13, 15, 16, 26, 57, 69,
 71, 75, 77–80, 101, 216
 eyewitness accounts, 70, 75
 ezogabine, 112, 196
- F**
 factitious disorder, 11, 81, 15
 families, 1, 3, 14, 18, 27, 39, 53,
 54, 55, 61, 63, 77, 82, 88,
 93, 106, 124, 166–7, 181,
 195, 211, 229, 234
 family planning, 194–5
 fasting, 80, 167–9
 fatigue, 168, 206, 233
 excessive, 168
 FBM, 130, 133–4, 136
 FDA, 123, 133, 207
 fear, 78, 102, 176, 205–6, 210,
 229–30, 232–3
 febrile seizures, 13, 87–8, 93,
 99, 124, 143, 173, 181–2
 felbamate, 112, 119–21, 125,
 130, 133, 136, 147, 206
 felodipine, 130–1
 females, 4, 13, 52, 75, 195, 223
 fertility, 153, 189–91, 194, 197
 fetal malformations, 144, 174,
 184
 fetus, 189, 197, 200
 fever, 95, 99, 220, 226
 fiber, 169
 fibromyalgia, 1, 2, 26, 27
 first seizure, 4, 55, 56, 57, 60,
 62, 66, 91, 100–5, 134, 215
 classifying, 57
 evaluating, 60
 First Seizure Study Trial
 Group, 104
 first-line agents, 108, 116–17,
 120, 127, 129, 212, 223,
 225
 first-line treatment, 115–16,
 212, 218–19, 222, 225
 flicker, 98, 161
 fluoxetine, 210
 flutter, 29
 flvoxamine, 210
 folate, 130–1, 153, 194–5, 197,
 199
 supplemental, 195
 folic acid, 194, 200
 folk practices, 154
 fosphenytoin, 219, 221, 224–5
 fracture, 216–17
 fragile X syndrome, 93
 frontal lobe, 7, 8, 16, 17, 43, 45
 frustration, 205, 211
- G**
 gabapentin, 70, 109–10, 118,
 123, 126, 130, 136, 141–2,
 147, 151, 160, 196, 206,
 213, 224
 GAD (generalized anxiety
 disorder), 206–7, 209
 ganglioglioma, 44, 47, 163, 201
 Gastaut syndrome, 72, 81, 87,
 93, 118–23, 160
 gastrointestinal symptoms,
 168
 gender, 4, 13, 16
 gene disorders, 93
 generalized anxiety disorder.
 See GAD
 genetics, 2, 3, 9, 35, 53, 54, 57,
 59, 60, 61, 62, 68, 85–8,
 90, 92–3, 98, 108–9, 112,
 119–20, 122–4, 141
 gliosis, 47, 91, 163
 globulin, 190, 211

Index

- glucose, 168, 220–1, 225–6
gonadal steroids, 128
grand mal seizures, 1, 2, 3, 6,
37, 51, 56, 57, 59, 62
griseofulvin, 131
- H**
- hallucinations, 5, 12, 58, 67,
72, 77–80, 208
 command, 208
 musical, 72
 report scenic, 80
 visual, 67
haloperidol, 131
hamartoma, 88, 163
Hamilton Anxiety Rating
 Scale, 207
head
 banging, 78, 81
 sensations, 74, 85
head banging, 12
head trauma, 30
headache, 9, 26, 37, 59, 82, 172,
200, 208
 migrainous, 82
healing practices, 154
heart, 79, 197, 218
hemifacial spasm, 9
hemiparesis, 9, 54
hemiplegia, 12
hemorrhage, 1, 43, 56, 61, 95,
134
hepatic failure, 112, 133, 135
herbal remedies, 154, 208
Heschl's gyrus, 72
heterotopias, 88, 163
hiccups, 81, 110
hippocampal sclerosis (HS),
45, 46, 47, 51, 61, 88,
91–4, 162–4, 184
HIV, 51
hoarseness, 165, 171
homeopathy, 154
hormones, 129, 189–91, 193,
195, 201, 211
HRT (hormone replacement
therapy), 201
HS. *See* hippocampal sclerosis
hunger, 80
 increased, 169
hydration, 225
hydro-cortisone, 117
hyperandrogenism, 191
hypercalcemia, 9, 56
hypercholesterolemia, 6, 56
hyperestrogenism, 201
hyperglycemia, 56
hyperinsulinemia, 153, 191
hyperlipidemia, 100
hypermotor behavior, 7
hypersensitivity reactions, 74,
99, 109–10, 113, 119
hypersomnia, 205–6
hypertension, 6, 9, 56, 191,
212
 included arterial, 100
hypertensive crises, inducing,
212
hyperthermia, 212
hyperventilation, 18, 68, 80
hypochondria, 74
hypochondriacal, 85
hypochondriacal tendencies,
85
hypoglycemia, 5, 9, 55, 56, 74,
80, 168, 221
 symptomatic, 168
hypoglycemic, 225
hypogonadism, 127
hyponatremia, 55, 56, 110,
119, 135, 151
hypospadias, 198
hypotension, 7, 223–6
hypothalamic hamartoma, 44,
61, 88
hypoxia, 218
 neonatal, 91, 127
- I**
- ictal fear, 7, 11, 28
ictal weeping, 15, 26
ICU (intensive care unit), 85,
218, 224, 225–7
Idiopathic Generalized
Epilepsies. *See* IGE
IEDs, 16, 17, 18, 29, 30, 32, 33,
34, 38, 49, 53, 62, 63
IGE (Idiopathic Generalized
Epilepsies), 86, 93, 110,
116–17, 119, 122, 160
ILAE (International League
Against Epilepsy), 66, 68,
85, 93, 109, 114
illicit drugs, 56
imepitoin, 112
imipramine, 212–13
immunoglobulin, 95
immunotherapy, 95
incontinence, 6, 11, 13, 28
independence, 230, 233
infants, 11, 83, 122, 124,
199–200
infections, 88, 218, 222–3, 227
infertility, 190–1
inflammation, 44
inheritance, 86–7
inhibitors, 124, 130–1
injury, 7, 13, 15, 27, 28, 43, 52,
54, 56, 57, 61, 68, 75, 91,
94, 97, 99, 117, 134, 150,
157, 161–2, 215, 218, 231,
233–4
 antecedent, 204
 head, 68, 134, 218
 ischemic, 117
 physical, 94, 157, 161
 severe brain, 150
 significant, 75
 traumatic brain, 91, 134, 218
insomnia, 200, 205–6, 209, 212
insulin, 80, 153
 serum, 153
insurance, 4, 16, 19, 199, 229,
231, 233
intelligence quotient (IQ), 90,
182, 195
intensive care unit. *See* ICU
International League Against
Epilepsy. *See* ILAE
interventions, 98, 146, 156–8,
161, 164, 167, 213, 217,
233
intractable epilepsy, 145, 165,
185
irritability, 11, 72, 205–6,
211–12
irritable bowel syndrome, 1,
26
ischemic attack, 9, 56, 57
isocarboxazid, 212
itraconazole, 131
IUDs, 195
- J**
- Jacksonian seizure, 67
Janz, Dieter, 89
jerking, 1, 6, 9, 51, 53, 58
jerks, 72–3, 79–82, 116, 122,
160, 189, 216
 hypnic, 81–2
 short, 80
jitteriness, 11
juvenile myoclonic epilepsy
(JME), 71, 86–7, 89, 93,
106, 114, 116, 132, 160,
179–81, 187, 189, 191, 229
juvenile myoclonic epilepsy, 9,
25, 35, 59, 62

K

kava, 207–8
 KD (ketogenic diet), 119, 124,
 156, 166–9
 ketamine, 223
 ketogenic diet. *See* KD
 kicking, 92
 kidney, 100, 110, 119, 128, 169
 kinetics, 148–9
 Kleffner syndrome, 87, 93

L

laceration, 1, 2, 28, 53, 54, 59
 lacosamide, 101, 112, 118–19,
 123, 126, 130, 136, 142,
 147, 152, 196
 lamotrigine, 1, 27, 51, 70,
 109–10, 118, 123, 125,
 130, 136, 140–2, 147, 160,
 174, 191, 194, 198, 206
 Landau–Kleffner syndrome,
 87, 93
 language, 9, 46, 58, 91, 95, 200,
 232
 laughter, 81, 84
 LCM, 128, 130, 136
 learning difficulties, 14
 learning disorders, 93
 Lennox–Gastaut syndrome,
 25, 60, 72, 81, 87, 93, 120,
 122–3, 160
 lesions, 9, 16, 17, 43, 45, 46,
 47, 48, 51, 55, 56, 57, 61,
 76, 91, 94, 163, 167, 215,
 220, 226
 amygdala, 92, 95
 lethargy, 202, 212
 leucopenia, 135
 LEV, 51, 60, 63
 levetiracetam, 70, 109–10, 112,
 118, 130, 142, 147, 151,
 191, 194–6, 198, 201, 204,
 219, 223–4
 levodopa, 80
 libido, 205
 decreased, 211
 reduced, 194
 life expectancy, 94
 lifestyle, 98, 161, 201, 229, 234
 seizure-averse, 179
 seizure-prone, 179
 seizure-provoking, 99
 light-headedness, 28, 79,
 206
 limb shaking, 82
 limbic encephalitis (LE), 92

limitations, 73, 77, 99–100,
 134, 148–9, 153, 213, 229
 lipids, 127–8, 153, 169
 lithium, 18, 55, 56, 63, 80, 130,
 211
 liver, 100, 110, 119, 132, 208
 lobectomy, 235
 lorazepam, 218–21, 223–6

M

magnesium citrate, 132
 magnets, 154, 165
 maintenance dosages, 144, 173
 major depressive disorder
 (MDD), 205, 209
 malaise, 80
 males, 13, 75, 150, 223
 malformations, 88, 90–1, 117,
 133, 143–4, 174, 195, 198
 malingering, 15
 malpractice, 20, 21
 management errors, 171–4
 management of epilepsy, 97,
 113, 119, 123, 150–1, 167,
 189
 mania, 208, 212
 mannerisms, 12, 81
 MAOIs, 211–12
 maprotyline, 210
 maximal electroshock seizure
 test, 137
 MDD (major depressive
 disorder), 205, 209
 mebendazole, 130–1
 medications, 18, 63
 medroxyprogesterone, 193
 medroxyprogesterone acetate,
 201
 memory, 46, 82, 90, 172, 233
 biographical, 78
 memory deficit, 89, 164
 memory performance, 92
 men, 75, 81, 84, 91–2, 149, 153,
 194, 208
 menarche, 94, 190, 192–3
 menopause, 189–90, 193, 201
 menses, 189–94
 menstrual periods, 192, 201
 mental retardation, 54
 mental status, 168, 227
 mephobarbital bromide, 112
 mesial TLE, 91, 184
 metabolic disturbances, 5
 metabolism, 113, 122, 128–9,
 167, 195, 202
 bone, 128
 fatty acid, 167
 hormone, 129, 195
 methadone, 130–1
 methotrexate, 131
 metoclopramide, 168
 metoprolol, 131
 metronidazole, 131
 midazolam, 221–4
 buccal, 222
 migraine, 5, 9, 12, 59, 74, 82–3,
 128–9
 mindfulness, 213
 MINI (Mini International
 Neuropsychiatric
 Interview), 208
 mirtazapine, 212
 miscarriages, 191, 195, 199
 misdiagnosis, 3, 4, 7, 12, 17,
 18, 20, 21, 25, 35, 39, 52,
 66, 74, 84, 143, 156, 171–2
 in children, 82
 misinterpretation, 27, 29, 32,
 34, 35, 40, 60
 mitochondrial
 encephalomyopathies, 93
 monitoring, 5, 18, 19, 25, 70,
 73–7, 80–1, 84, 91–2,
 140–1, 144, 146–9, 162–3,
 167–9, 174, 176, 211, 213,
 224–7
 presurgical, 162
 monoamine oxidase inhibitors
 (MAOIs), 211
 mood, 21, 52, 72, 77, 93, 110,
 205–7, 209, 212–13, 232
 morbidity, 4, 7, 20, 77, 87, 117,
 127, 137, 149, 151, 157,
 164, 202, 205, 215, 217,
 219, 224
 associated, 202
 increased, 219
 neurological, 224
 significant, 205
 mortality, 4, 7, 20, 90, 137, 157,
 189, 202, 205, 217, 219,
 221, 224, 227
 high, 222
 higher, 94
 hospital, 222
 increased, 150
 lower, 99
 mothers, 101, 195, 197,
 199–200
 movement disorder, 5, 9, 16, 20
 movements, involuntary, 74,
 83, 85

Index

- MRC AED Withdrawal Study, 181
 MTLE (mesial temporal lobe epilepsy), 88, 91–3, 153, 162–4, 184
 MTS, 163
 Multicentre Study of Early Epilepsy and Single Seizures, 103
 multiple sclerosis, 9
 Münchhausen syndrome, 220, 226
 muscle contractions, 216–17
 muscle relaxants, 130–1
 muscles, 9
 myocardial infarction, 129
 myoclonias, 143, 160, 172
 eyelid, 67–9
 negative, 161
 perioral reflex, 98, 161
 myoclonic absences, 67, 69, 87
 myoclonic jerks, 73, 79, 82, 116, 122
 myoclonic seizures, 9, 60, 68–71, 94, 110, 116, 119, 122, 124, 172, 179, 181, 220, 226
 series of, 179
 myoclonus, 5, 7, 9, 11, 54, 59
- N**
 narcolepsy, 81
 National Institute for Clinical Excellence, 109
 natural products, 208
 nausea, 7, 28, 79, 168, 200
 NCSE, 72–3
 NEEs, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 14, 16, 17, 18, 19, 20, 21
 neonates, 11
 nephrolithiasis, 135, 166
 neural tube defects, 195, 198
 neurocutaneous syndrome, 45
 neurodegenerative diseases, 81, 150
 neurological deficits, 89, 102, 134, 178
 Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), 207
 neurological examination, 102, 190, 216, 220, 226
 neurostimulation, 156, 162, 165
 neurotoxicity, 130–1, 144, 149, 174
 newborns, 200
 new-onset epilepsy, 66, 99–100, 103, 108–10, 113, 115–17, 119, 129, 132–3, 140–1, 150, 172, 175, 183–4, 187
 new-onset West Syndrome, 117
 NFLE (Nocturnal frontal lobe epilepsy), 84, 87, 92
 nifedipine, 130–1
 night terrors, 5, 7, 78, 81
 nightmares, 5, 7, 78, 81
 nimodipine, 130–1
 N-methyl-D-aspartate receptor (NMDAR), 95
 N-Methyl-D-aspartic acid, 192
 nocturnal frontal lobe epilepsy. *See* NFLE
 nocturnal seizures, 53
 noncompliance, 142, 152, 180, 231
 non-convulsive seizures, 59
 nonconvulsive status epilepticus, 39
 non-EIAEDs, 194–5
 non-epileptic events (NEEs), 1, 25
 non-epileptic myoclonus, 9
 nonepileptic seizures, 74, 78, 94, 173, 220, 226
 non-psychogenic conditions, 81, 83
 norepinephrine, 227
 North American Antiepileptic Drug trial, 200
 nortriptyline, 212
 NSAIDs, 204
 numbness, 9, 58
- O**
 obesity, 153, 191
 observational studies, 101, 124, 183, 223
 Occam's razor, 168
 occupational therapist, 82, 192
 OCPs (Oral contraceptive pills), 193, 195
 Ohtahara syndrome, 87
 oligomenorrhea, 189, 191
 opisthotonus, 79
 oral contraceptive pills. *See* OCPs
 osteoporosis, 109, 127–8, 135, 151, 201–2
 outcomes, 103–4, 115, 154, 164, 181, 195, 222, 227, 229, 234
 out-of-phase activity, 26
 over-diagnosis, 20
 over-interpretation, 29, 39, 40
 overtreatment, 3, 6, 21, 136, 140, 143–5, 151, 171–5
 inadvertent, 143–4, 171, 174
 overweight, 109, 128, 190
 ovulation, 190–3
 OXC, 113–16, 128–30, 133, 136, 151–3, 209–10
 oxcarbazepine, 70, 109–10, 123, 125, 130, 136, 141–2, 147, 151, 196, 209, 213
- P**
 pacemaker, 79, 165
 palliative care, 156, 162, 166
 pallor, 6, 7, 28, 79
 Panayiotopoulos syndrome, 87, 93, 182
 pancreatitis, 135, 169
 panic, 11, 12
 panic attacks, 74, 77–8, 206
 paraldehyde, 222
 parasomnias, 5, 7, 12, 81, 84, 92
 paresthesia, 9, 11
 Parkinson's disease, 7
 Parkinsonian syndromes, 84
 paroxetine, 209–10, 212
 partial epilepsy, 91, 99, 153, 159, 162, 165, 183
 partial seizures, 67, 70, 93–4, 98, 101, 105, 110, 112, 142, 145, 159, 161, 179–80, 223, 226
 Passionflower extracts, 208
 patients
 high-risk, 104, 175
 photosensitive, 98, 161
 untreated, 104, 140, 145
 PB, 111, 122, 128–31, 133, 136, 142, 145–6, 152–3, 204, 206
 PCP (primary care physicians), 204, 206–8, 229, 231
 pediatricians, 122, 167, 200
 pentobarbital, 222–4, 226

- perampanel, 112, 118–19,
141–2, 196, 206
- perimenopause, 193, 201
- PGB, 117, 119, 133
- P-glycoprotein, 157
- PGN, 128–9, 131, 136
- PGTCS, 70–1
- pH, 225
- pharmacokinetics, 108, 111,
114, 117, 120, 122, 127–8,
132, 144, 148–9, 151, 153,
174, 208, 210
altered, 148–9
- phase reversals, 18, 27, 36, 40
- phenelzine, 212
- phenobarbital, 111–12,
118–20, 123, 126, 129,
131, 173, 196, 198, 204,
206, 210–11, 218–19,
222–4, 226
intravenous, 222
major metabolite, 176
- phenobarbital/phenytoin, 112
- phenobarbital/primidone, 119
- phenobarbitone, 142
- phenytoin, 55, 57, 59, 60, 101,
111–12, 118–20, 123, 125,
129, 131, 136, 142, 147,
191, 196, 198–200, 210,
218–25
- phenytoin-equivalents (PE),
221
- pheochromocytoma, 5
- phobias, 77–8, 206
- phonations, 79
- photic stimulation, 18, 30, 31
- PHT, 111, 113–16, 122, 128–9,
131–3, 136, 142, 145–9,
152–3, 159–60, 176
- piracetam, 123
- polycystic ovarian syndrome
(PCOS), 190
- polycystic ovaries, 152,
190–1
- polypharmacy, 144, 174, 185
- polytherapy, 134, 146–7, 149,
184, 198
- prometrium, 193
- porphyria, 167
- postictal psychosis, 72, 208
- posttraumatic epilepsy, 82,
134, 162
- post-traumatic stress disorder
(PTSD), 5, 14, 16, 26
- posture, 58, 67
- potassium bromide, 111
- pregabalin, 27, 70, 112, 126,
128, 131, 136, 147, 191,
201, 206, 213
- Pregabalinb, 123
- pregnancy, 32, 33, 51, 52, 94,
143, 147–8, 189, 194–200
high-risk, 198
plan, 195
teenage, 94
unplanned, 195
- prevention, 98, 124, 137, 161,
223
- primary care physicians. *See*
PCP
- primidone, 70, 111–12, 120–1,
123, 131, 142, 147, 176,
196, 206, 210–11
- privitera, 113
- progesterone, 190, 192–3, 201
- prolactin, 13, 76, 95, 190
elevate serum, 194
- promethazine, 168
- propranolol, 131, 213
- protein, 89, 166, 199–200
- protriptyline, 212
- provoked seizures, 55, 56
- psychiatric disorders, 5, 11, 14,
16, 74, 77–8, 81–3, 204,
207–8, 221, 227, 229
- psychiatrists, 77, 186, 207, 209
- psychopathology, 14
- psychosis, 72, 95, 204, 208–9
- psychosocial complications,
229, 232
- psychosocial problems, 157,
161, 229
- puberty, 93, 190, 192
- pulse, 29
- pyruvate carboxylase, 167
- pyruvate dehydrogenase, 167
- Q**
- QT syndrome, 5, 7
- quality of life, 100, 104, 137,
150, 154, 157, 164, 178,
204, 206, 229, 232–4
impaired, 232, 234
- Quality of Life in Epilepsy
Inventory, 232
- quinidine, 130–1
- R**
- radiosurgery, 156, 162
- randomized controlled trials
(RCTs), 97, 102–4, 106,
114, 145, 181
- ransaminases, 132
- rasagiline, 212
- rash, 119, 132, 135, 160
facial, 190
- Rasmussen syndrome, 44,
215
- RCTs. *See* randomized
controlled trials
- recommended AEDs for new-
onset epilepsy, 140
- recovery, 79, 95, 215, 218–20
- recurrence, 49, 51, 52, 53, 54,
55, 56, 57, 58, 60, 61, 62,
63, 65, 90, 97–106, 150,
164, 175–6, 178–84, 186–
7, 209, 215, 218, 222–5
- reflex epilepsies, 28, 88, 98, 161
- reflux, gastroesophageal, 81,
168–9
- refractory epilepsy, 109, 111,
113, 117–21, 134, 137,
146, 161, 166, 173, 175
- refractory GCSE, 221, 223–4
- relapse, 90, 95, 158, 172,
176–7, 179, 181, 183–4,
186–7, 209
higher risk of, 177, 180–1
late, 103
risk of, 102, 177, 180, 183
- relationships, 144, 174, 232,
234
- relatives, 77, 99–100, 185,
216
- religious healing, 154
- REM sleep, 81, 84
- REM sleep behavior disorders
(RBD), 84
- REM-behavioral disorder,
74, 81
- remission, 20, 52, 89–90,
102–4, 106, 115, 144,
146, 156, 158, 164, 172,
176–85, 207
2-year, 102–4
complete, 176
document symptom, 207
late, 177
long-term, 90, 183–4
prolonged, 177
- reproductive years, 116, 128,
190, 197
- resective surgery, 17, 91, 99,
153, 162, 165–6
- restlessness, 78, 206, 212
- retigabine (ezogabine), 112,
118–19, 126

Index

- risk
 adverse, 198
 cumulative, 90
 decreased, 200
 high, 89, 103–4, 180
 higher, 104, 147, 162, 177, 179, 195
 higher-than-average, 180
 highest, 104
 increased, 82, 90, 109, 123, 133, 143, 150, 165, 179, 181, 186, 198–9, 201, 233
 individual, 97, 103, 182, 184, 186
 intermediate, 198
 low, 103–4, 110, 123, 132, 224
 lower-than-average, 181
 medium, 102–4
 minimum, 124, 137
 potential, 171, 225
 seizure-related, 94
 significant, 157, 161, 231
 sixfold, 150
 vascular, 128
- risk factors, 13, 49, 61, 62, 82, 88, 90, 101, 179, 208–9, 215
 cardiovascular, 153
 common, 150
 independent, 101
 major, 208
- risk-benefit profile, 110, 117, 156
 optimal, 108
- risk-to-benefit ratio, 144, 149, 162, 172, 174, 184
 individual, 184
- rituximab, 95
- rodent models, 125–6
- rosenroot, 208
- rufinamide, 120, 122, 136, 147, 196
- S**
- safety, 97, 108, 113, 117, 119, 127, 132–3, 211, 234
 precautions, 199, 233
- SAMe, 70, 93–4, 116, 129, 133, 137, 144, 160, 174, 179, 206, 208, 210, 212, 230
- SANAD trial, 115–16
- Sandifer's syndrome, 11
- sclerosis, 32, 44, 47, 88, 91–4, 117, 162–4, 167, 184, 204–5
- SCN1A gene, 124
- scotomata, 58
- screaming, 92
- sedation, 110, 119, 130, 159, 219, 224
- seizure activity, 71, 73, 193, 215, 217–18, 221–2, 224, 225
- seizure aggravation, 160–1, 194, 199
- seizure duration, 16
- seizure frequency, 144–5, 154, 156–7, 159, 164, 166, 173–7, 190, 192–3, 195, 197, 199, 201, 204, 206
 patient's, 156
 pre-treatment, 177
 reduction of, 144–5, 154, 157, 159, 164, 166, 173–4, 176, 185, 190, 192–3, 195, 201, 204, 206
- seizure misdiagnosis, 50
- seizure onset, 16, 36, 54, 58, 67, 79–80, 86, 88, 93–4, 178, 180, 182, 208
- seizure recurrence, 90, 97–105, 150, 164, 175–6, 178–84, 215
 risk of, 97
- seizure remission, 89–90, 106, 115, 144, 156, 178–9, 183
- seizure resistance, 162
- seizure-freedom, 100, 103, 119–20, 122, 137, 140–1, 143–4, 156–8, 161, 163–4, 172, 177–9, 183–4, 186, 230–1
 permanent, 103, 177
- selegiline, 212
- self-efficacy, 233–4
- self-esteem, 230, 232–5
- self-image, 234
- self-limiting epilepsy, 182
- self-management, 229, 233
 hazardous, 234
- semiology, 3, 5, 14, 16, 18, 27, 46, 48, 58, 59, 60
- sensations, 74, 79, 85
- sensitivity, 4, 5, 15, 18, 30, 48, 76, 115, 151, 157
- sepsis, 5, 55, 56
- serotonin syndrome, 212
- sertraline, 210–11
- sex hormones, 190, 211
- sexual abuse, 1, 2, 12, 13, 27, 37, 75
- sexual functions, 153, 194, 211
- sexuality, 189, 194
- SGTCS, 70–1, 91
- shaking, 9, 10, 15, 26
- siblings, 18, 61, 63
- sick sinus syndrome, 7
- side-to-side head movement, 26, 27
- simple partial (SPS), 70
- skin rashes, 116, 122
- sleep, 4, 5, 7, 13, 15, 16, 20, 26, 29, 30, 33, 34, 37, 38, 57, 71, 74–5, 78–9, 81, 84, 87, 89, 92–3, 98–9, 161, 199, 201, 229, 231, 234
 deprivation, 79, 81, 99, 199
 disorders, 74, 84, 92
 slow wave, 92
- slumping, 80
- smoking, 197, 202
- social difficulties, 14
- social issues, 229–36
- Society for Neurology, 109
- somatization disorders, 12, 15
- somnambulism, 5, 7
- somnolence, 136, 193
- spasms, 67, 69, 167
- speech, 57
- sperm, 153
- spike-driving, 29, 30, 31
- spiritual healing, 154
- spitting, 16
- SSRIs (selective serotonin reuptake inhibitor), 207, 210–13
- St. John's Wort, 207–8
- staring, 58, 59, 79, 81
 blank, 192, 201
- startle, 5, 9
- State-Trait Anxiety Scale, 207
- status epilepticus, 71–3, 75, 91, 94, 112, 119, 124, 127, 150, 160–1, 185, 215, 217, 220–7
 convulsive, 220, 226
 generalized convulsive, 73, 221
 nonconvulsive, 71–2, 119, 160
 refractory generalized convulsive, 223–4
- steroids, 10, 128, 189–90
- Stevens–Johnson syndrome, 25, 123, 133
- stickiness, 72
- stiffening, 92
- stiffness, 11
- stigma, 97, 232–3
- stiripentol/rufinamide, 112

- stress, 98, 161, 197, 209, 234
 acute, 75
 emotional, 70
 reducing, 229, 234
 test, 197
- stroke, 9, 13, 56, 57, 88, 94,
 129, 150, 215, 218
 acute, 218
- stuttering, 77
- substance abuse, 94, 98, 161,
 220, 226
- suicidal ideation, 133, 205,
 208, 213
- sulthiame, 112, 120
- supplements, 149, 202, 208
 bicarbonate, 166
 over-the-counter, 208
- surgery, 90, 120, 154, 156, 158,
 161–6, 169, 183–5, 196, 235
- sweating, 7, 28, 79
- symptomatic seizure, 61
- syncope, 5, 6, 7, 8, 11, 13, 15,
 20, 28, 29, 30, 51, 53, 69,
 74, 77–80, 82–3, 143, 151,
 172–3, 185, 216
 diagnosing, 79
- T**
- tachycardia, 168
- tacrolimus, 131
- tamoxifen, 131
- television, 98, 161
- temperature, 225, 227, 234
- temporal lobe, 67, 69, 71–2,
 79, 88–9, 91–2, 94, 150,
 153, 162–4, 184, 208
- temporal lobe epilepsy, 18, 25,
 32, 34, 43, 45, 46
- terminology, 40, 65, 67, 69
- terrors, 78, 81
- testosterone, 153, 190–1
- tetanus, 5
- TGB, 112, 116, 128–9, 131,
 133, 136, 160
- theophylline, 130–1
- therapeutic index, 144, 174
- therapy
 dietary, 166, 168
 exercise, 213
 first-line, 116, 122, 167, 219
 interpersonal, 213
 massage, 154
 medical, 154, 164, 167
 mind-body, 154
 pharmacological, 143, 173
 psychiatric, 213
 relaxation, 154
 single-drug, 185
- thiamine, 221, 225
- thiopental sodium, 224
- thrombopenia, 135
- thrusting, 77
- tiagabine, 73, 112, 118–21,
 125, 131, 136, 142, 147,
 160, 206, 213
- tiagabineb, 123
- TIAs. *See* transient ischemic
 attack (TIA)
- tics, 5, 9, 12, 81
- tigabine, 196
- tilt-table test, 20
- tingling, 58
- tissue plasminogen activator
 (TPA), 9
- TLE. *See* Temporal lobe
 epilepsy
- Todd paralysis, 9, 82
- Todd's paresis, 94
- Todd's phenomenon, 53, 54,
 61
- tolerability, 108, 111, 113–15,
 117, 120, 127, 133–4,
 136–7, 140, 152, 211, 223
- tone, 68, 81
- tongue, 1, 2, 4, 13, 15, 28, 53,
 54, 55, 59, 63
- tongue biting, 75, 216
- topiramate, 70, 109–10,
 118–19, 123, 125, 131,
 136, 141–2, 147, 152, 161,
 191, 198, 206, 223–4
- Tourette's syndrome, 12
- toxicity, 99, 129, 131–2, 141–5,
 147–8, 154, 174, 185, 200,
 211
- tramadol, 55
- transient ischemic attack
 (TIA), 5, 9, 10, 57, 74, 82
- tranylcypromine, 212
- trauma, 12, 26, 56
- trazodone, 80, 213
- tremor, 5, 9, 11, 13, 15, 36, 80,
 85, 129, 206, 212
- trials, 97, 102–4, 106, 113–15,
 117, 119, 132–3, 154, 156,
 158–60, 164, 166, 178–9,
 207, 210–11
 adequate, 156, 159–60
 controlled, 97, 102–4, 106,
 114–15, 119, 145, 154,
 163–4, 166, 178–9, 181,
 183, 207, 211, 223
- nonrandomized, 164
 regulatory, 115, 133
- triggers, 7, 15, 16, 28, 55, 56
- triglycerides, 153, 169
- trihexyphenidyl, 80
- trimethadione, 111
- trimipramine, 212
- tubal ligation, 195–6
- tuberous sclerosis, 88, 117, 167
- tumor, 88, 95, 163
 associated, 95
- tumor resection, 95
- tumors, 47, 92, 150
- twitches, 83, 85
- twitching, 59, 60
- U**
- unclassifiable epilepsies, 93
- uncontrolled epilepsy, 144,
 158, 185
- undertreatment, 144,
 171–2
- unprovoked seizures, 52, 53,
 55, 56, 57, 61, 105
 recurrent, 92
- unresponsiveness, 3, 12, 26,
 82–3, 95
- unsteady gait, 60
- urine, 79, 169
- US Food and Drug
 Administration, 133
- V**
- vagus nerve stimulation, 162,
 165–6
- valproate, 1, 60, 70, 89, 108–10,
 118, 122–3, 125, 131,
 141–2, 147, 179, 189, 191,
 219–20, 223–5, 229
 intravenous, 222
 sodium, 140
- Valsalva maneuver, 6, 80
- vascular malformations, 46
- vasectomy, 195–6
- vasopressors, 224, 225
- venlafaxine, 210–12
- verapamil, 130–1
- vertigo, 5, 11
- Veterans Affairs (VA),
 218
- VGB, 112, 116–17, 120, 128,
 131, 133–4, 136
- vigabatrin, 73, 112, 119, 121,
 123, 131, 136, 142, 147,
 160, 196, 206

Index

- viral illnesses, 168–9
 visual disturbances, 202
 visual field defects, 117, 119, 133
 vitamin B, 95
 vitamin B6, 220, 226
 vitamin D, 128, 153, 202
 vitamin K, 197, 200
 vocalizations, 16, 79, 84
 voice, 165
 vomiting, 168–9
 VPA, 108–9, 111–17, 122, 124, 128–9, 131–4, 136, 140–1, 143–6, 151–3, 159–61, 179, 189, 191, 198
- W**
- waking, 82, 88–9, 106
 weakness, 9, 11, 56, 75, 80, 82, 100
- WebEase (Epilepsy Awareness Support and Education), 234
 weeping, 77
 weight, 128, 152, 191
 change, 136, 152
 decreasing, 181
 gain, 116, 122, 191, 193, 211
 loss, 128, 152, 191, 206
 well-being, 100, 104, 178, 233
 West syndrome, 87, 119
 wicket spikes, 18, 29, 34, 63
 witnesses, 66, 83, 151, 220, 226, 233
 women, 91, 95, 122, 133, 143–4, 148–9, 174, 184, 189–202
 black, 95
 of childbearing age, 109, 189
 treatment of, 116
 untreated, 113
 white, 95
 young, 75, 190
 women with epilepsy (WWE), 189–201
 postmenopausal, 201–2
- X**
- X-ray, 43
- Y**
- yoga, 154
- Z**
- ZNS, 117, 128, 136, 206
 zone outs, 3
 zonisamide, 70, 112, 118–19, 125, 133, 136, 142, 147, 168, 191, 196, 206